Prior treatment with oxaliplatin-containing regimens and higher total bilirubin levels are risk factors for neutropenia and febrile neutropenia in patients with gastric or esophagogastric junction cancer receiving weekly paclitaxel and ramucirumab therapy: a single center retrospective study

MLA

Nara, Katsuhiko, et al. “Prior Treatment with Oxaliplatin-Containing Regimens and Higher Total Bilirubin Levels Are Risk Factors for Neutropenia and Febrile Neutropenia in Patients with Gastric or Esophagogastric Junction Cancer Receiving Weekly Paclitaxel and Ramucirumab Therapy: A Single Center Retrospective Study.” BMC Cancer, vol. 23, no. 1, Oct. 2023, pp. 1–9. EBSCOhost, https://doi.org/10.1186/s12885-023-11469-y.

APA

Nara, K., Yamamoto, T., Yamashita, H., Yagi, K., Takada, T., Seto, Y., & Suzuki, H. (2023). Prior treatment with oxaliplatin-containing regimens and higher total bilirubin levels are risk factors for neutropenia and febrile neutropenia in patients with gastric or esophagogastric junction cancer receiving weekly paclitaxel and ramucirumab therapy: a single center retrospective study. BMC Cancer, 23(1), 1–9. https://doi.org/10.1186/s12885-023-11469-y

Chicago

Nara, Katsuhiko, Takehito Yamamoto, Hiroharu Yamashita, Koichi Yagi, Tappei Takada, Yasuyuki Seto, and Hiroshi Suzuki. 2023. “Prior Treatment with Oxaliplatin-Containing Regimens and Higher Total Bilirubin Levels Are Risk Factors for Neutropenia and Febrile Neutropenia in Patients with Gastric or Esophagogastric Junction Cancer Receiving Weekly Paclitaxel and Ramucirumab Therapy: A Single Center Retrospective Study.” BMC Cancer 23 (1): 1–9. doi:10.1186/s12885-023-11469-y.